A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Study sponsor: Kodiak Sciences Inc · KOD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-10Actual
Enrollment · participants568Actual
Source updated2024-06-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.